Treatment of multiple myeloma with selinexor: a review.

IF 3.4 3区医学 Q2 HEMATOLOGY

Therapeutic Advances in Hematology Pub Date : 2024-01-05 eCollection Date: 2024-01-01 DOI:10.1177/20406207231219442

Qianlei Huang, Ranran Zhao, Lu Xu, Xinbao Hao, Shi Tao

引用次数: 0

Abstract

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a very poor outcome. Therefore, it is necessary to explore new drugs for the treatment of MM. This review summarizes the mechanism of action of selinexor, relevant primary clinical trials, and recent developments in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma. Selinexor may be useful for the treatment of refractory MM.

查看原文本刊更多论文

西利奈克索治疗多发性骨髓瘤：综述。

在过去的 20 年里，治疗多发性骨髓瘤（MM）的疗法取得了突破性进展。然而，对免疫调节药物、蛋白酶体抑制剂和抗CD38单克隆抗体产生抗药性的多发性骨髓瘤患者的预后非常差。因此，有必要探索治疗 MM 的新药。本综述总结了西利昔多的作用机制、相关的主要临床试验以及在复发/难治性骨髓瘤患者和新诊断骨髓瘤患者中的最新进展。Selinexor可能有助于治疗难治性骨髓瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Hematology HEMATOLOGY-

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

7 weeks

期刊介绍： Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.